Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Signs Zebrafish Gene Function Deal with AVI BioPharma

NEW YORK, April 27 – Exelixis and AVI BioPharma have agreed to partner in a drug development alliance using Exelixis’ zebrafish functional genomics technologies and AVI’s antisense agents, the companies said Friday.

In a five-year agreement, AVI, of Portland, Oregon, will provide its Neugene morpholino antisense agents to Exelixis subsidiary Artemis Pharmaceuticals, which Exelixis acquired on Monday in a stock-for-stock transaction valued at more than $24 million. Artemis, of Tubingen, Germany, will use the antisense agents to block the expression of specific genes in zebrafish and other model organisms to determine the genes' functions and identify targets for drugs.

Because AVI’s antisense agents inhibit gene function, they could also potentially act as drugs themselves. As part of the deal, AVI will have responsibility for designing antisense agents and conducting preclinical and clinical trials on those antisense agents with potential as therapeutics.

Exelixis will pay AVI for manufacturing the antisense agents used in the animal model studies through the five years of the agreement, and the two companies will jointly own any antisense products that they develop. Exelixis, of South San Francisco, also has the option to co-develop promising antisense agents that the two companies identify. Other financial details were not disclosed.

"Key to this agreement is the quick development time it promises,” Denis Burger, AVI’s CEO said in a statement. “When we define the function of a gene with Neugenes, we don't have to go back and spend three to five years in drug development, because the Neugene antisense agent that was used to define gene function is the drug.”  
The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.